Kibow Biotech, Inc. Secures $2.4 Million Towards Its Human Clinical Trials by Continued Veterinary Licensing Agreement
NEWTOWN SQUARE, Pa., Aug. 24, 2011 /PRNewswire/ -- Kibow Biotech, Inc. today announced that it has renewed its exclusive worldwide licensing and marketing agreement with the current licensing partner specializing in animal health. The agreement concerns "Azodyl™," a patented, 100% natural, probiotic dietary supplement indicated for the reduction of azotemia in dogs and cats with moderate to severe renal failure. Developed by Kibow, Azodyl™ has been successfully marketed and sold mainly in USA and Canada since July 2006.
Kibow intends to utilize a major portion of the $2.4 million funding secured for testing a similar, patented, probiotic dietary supplement intended for human consumption. This flagship product, known as "Kibow Biotics™," is targeted towards kidney health and helps improve the quality of life in chronic kidney failure (CKF) patients who also adhere to their routine standardized care of treatment for their pre-existing medical conditions.
Kibow's human clinical trials, involving dialysis and pre-dialysis patients, have already been initiated at Thomas Jefferson University, Philadelphia, PA and at Downstate Medical Center/Kings County Hospitals, State University of New York (SUNY), Brooklyn, NY. Another trial, to be conducted at Mayo clinic, Rochester, MN is soon to begin.
About kidney failure in companion animals:
A leading cause of death among geriatric cats and dogs, "kidney failure" or "renal failure" refers to persistent azotemia, a build-up of uremic toxins in the blood, usually caused by a loss of nephron function in the kidneys.
About Kibow Biotech:
Kibow Biotech, Inc. is a 13-year-old R&D biotechnology company, having its operations in Newtown Square, PA, USA. The company's mission to find a simple, convenient and cost-effective worldwide solution for people experiencing kidney function problems. The company's flagship product is called "Kibow(R) Biotics," an orally consumable, enteric-coated gel cap product formulation that is composed of food-grade microbes ("Probiotics") which metabolize the uremic toxins diffusing into the bowel as a consequence of increased levels of these toxins in the blood. The purpose of this non-drug dietary supplement product is to help maintain a healthy kidney function for people in need of alternative or complementary Over The Counter (OTC) products.
For more information: Dr. N. Ranganathan, Ph.D., Phone: 610 353-5130, http://www.kibowbiotech.com
SOURCE Kibow Biotech, Inc.